Condition: Developmental Delay · Sponsor: IDeA States Pediatric Clinical Trials Network
The INTACT trial is a multisite pilot feasibility study aimed at testing the effectiveness of the INTACT Intervention program in improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. The trial will enroll 20 birthing parent/infant dyads across three sites and will evaluate feasibility endpoints rather than clinical outcomes. The study duration is 22 months, including study start-up, enrollment and intervention, and data analysis and manuscript preparation.
This description comes directly from the study's public registry record.
Song Ounpraseuth, PhD · (501) 686-5647 · STOunpraseuth@uams.edu
Matthew Henry, MSc · (501) 686-5647 · mhenry3@uams.edu
Always discuss trial participation with your own doctor first.
| University of New Mexico Health Sciences Center | Albuquerque, New Mexico, United States | Recruiting |
| Avera Research Institute | Sioux Falls, South Dakota, United States | Recruiting |
| University of Vermont Medical Center | Burlington, Vermont, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06423664